Aquestive Therapeutics, Inc. (AQST)

Market Cap	431.73M
Revenue (ttm)	58.90M
Net Income (ttm)	-35.19M
Shares Out	91.18M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,259,449
Open	4.810
Previous Close	4.820
Day's Range	4.635 - 4.880
52-Week Range	1.840 - 6.230
Beta	2.81
Analysts	Strong Buy
Price Target	9.43 (+99.16%)
Earnings Date	Nov 4, 2024

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 25, 2018
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: AQST
• Website: https://www.aquestive.com

Financial Performance

In 2023, Aquestive Therapeutics's revenue was $50.58 million, an increase of 6.09% compared to the previous year's $47.68 million. Losses were -$7.87 million, -85.54% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $9.43, which is an increase of 99.16% from the latest price.

Price Target

$9.43

(99.16% upside)

Analyst Consensus: Strong Buy